VolitionRx Limited (VNRX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by VolitionRx Limited on February 20, 2026, covering events occurring on February 17, 2026. The company is incorporated in Delaware and trades on NYSE American under the symbol VNRX. The filing primarily addresses unregistered sales of equity securities related to debt repayment and a prior private placement.
Key Financial Metrics and Transactions
The filing details specific equity issuances rather than standard financial performance metrics like revenue or cash flow. Key transactional data includes:
- Debt Instrument: A senior secured convertible promissory note with a principal amount of $7,500,000 issued to Lind Global Asset Management XII LLC ("Lind").
- February 17, 2026 Issuance: 1,956,178 shares of common stock issued to Lind to satisfy a $416,666 payment obligation.
- January 29, 2026 Issuance: 2,569,753 shares of common stock issued to Lind to satisfy a $583,334 payment obligation.
- January 16, 2026 Issuance: 1,893,936 shares of common stock issued to Lind to satisfy a $416,666 payment obligation.
- September 18, 2025 Private Placement: Issuance of 483,870 shares plus warrants for 483,870 shares (exercise price $0.682) to an existing stockholder for $300,000.
The filing text does not provide clear values for total revenue, net profit, operating cash flow, gross margins, total debt outstanding, or liquidity ratios.
Material Changes and Unusual Items
The material change reported is the conversion of debt obligations into equity. Between January 16 and February 17, 2026, the Company issued a total of 6,419,867 shares of common stock to Lind Global Asset Management XII LLC to satisfy approximately $1,416,666 in payment obligations under the convertible note. Additionally, the filing reiterates a private placement from September 2025 involving stock and warrants.
Guidance, Outlook, and Risks
The filing does not contain management commentary, forward-looking guidance, or specific risk factors beyond the standard disclosure of the securities exemptions used. The transactions were executed under exemptions from registration under Section 3(a)(9), Section 4(a)(2) of the Securities Act, and/or Rule 506 of Regulation D. No public offering or general solicitation was involved.
Investor Verification Checklist
- Verify the total number of shares outstanding post-issuance to assess dilution impact from the 6.4 million shares issued to Lind in Q1 2026.
- Confirm the remaining principal balance on the $7,500,000 senior secured convertible note after the recent payments.
- Review the terms of the warrants issued in September 2025 (exercise price $0.682, expiration September 2030) for potential future dilution.
- Check subsequent filings for any updates on the company's liquidity position given the reliance on debt-to-equity conversions for payments.